This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Meningococcal Meningitis, Serogroup A
+4

Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults

Sponsored by Prof. Elizabeth Miller

About this trial

Last updated 7 years ago

Study ID

MenOccy

Status

Completed

Type

Interventional

Phase

Phase 2

Placebo

No

Accepting

18-75 Years
18 to 65 Years
All
All

Trial Timing

Ended 13 years ago

What is this trial about?

The study involves the measurement of immune response to vaccination with three doses of a meningococcal B vaccine and a single dose of a meningococcal ACYW conjugate vaccine in healthy adults (Laboratory workers). The study will be completed at the Manchester Medical Microbiology Partnership in the UK and will enrol staff who may be at potential occupational exposure to meningococci. Blood samples will be taken before and after each vaccination and used to determine if the vaccines induce protective responses.

What are the participation requirements?

Yes

Inclusion Criteria

- Aged 18-65 years of age

- Who have given written informed consent after the nature of the study has been explained.

- Who work within the Manchester Medical Microbiology Partnership and may be at potential occupational exposure to meningococci.

No

Exclusion Criteria

- The possibility of pregnancy

- A serious chronic disease including progressive neurological disease or seizure disorder.

- Have a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.

- Have a history of severe allergic reactions after previous vaccinations such as anaphylactic shock, asthma, urticaria, or other allergic reaction or hypersensitivity to any vaccine component.

- Have received another investigational agent within 90 days or before completion of the safety follow-up period in another study, whichever is longer, prior to enrollment and unwilling to refuse participation in another investigational trial through the end of the study.

Locations

Location

Status